Navigation Links
Dan Broderick Joins Prolog Ventures as Partner
Date:9/12/2007

ST. LOUIS, Sept. 12 /PRNewswire/ -- Prolog Ventures, a venture capital firm specializing in life science investments, today announced that Dan Broderick has joined the firm as its fourth partner. Broderick brings more than 20 years of experience in early-stage investing, venture fund management, and technology commercialization.

Before coming to Prolog, Broderick was a managing director at Mason Wells in Milwaukee, WI, where he served on its board of directors and management committee and managed the Mason Wells Biomedical Fund -- the firm's first venture capital fund. Prior to this, he spent 18 years at the Mayo Clinic in Rochester, MN, where he served as director of technology commercialization for 12 years and co-launched the clinic's corporate venture capital fund.

"Dan's extensive industry experience and deal flow connections further strengthen Prolog's expertise in early-stage life science investing," said Ilya Nykin, managing director of Prolog. "He was involved in the creation, financing, and growth of more than 20 venture-backed companies in Prolog's core areas of focus, most of them early-stage. Having Dan on Prolog's team is a great boost to our mission of translating life science breakthroughs into successful ventures."

Broderick's professional accomplishments have prompted a number of prominent industry boards and advisory panels to seek his involvement. He is a member of the board of directors of the National Venture Capital Association and the chair of its Research Committee; a trustee of both the Medical College of Wisconsin and the University of Wisconsin-Milwaukee Research Foundations; a member of the University of Minnesota Business Development Advisory Board; and a charter member of the venture capital advisory board of BioGenerator, a St. Louis nonprofit seed-capital investment fund.

"Not only is Dan an astute investor, but he is also a long-time colleague. We have an excellent track record of working together," said Greg Johnson, managing director of Prolog. "I met Dan 15 years ago, and over the years, we've collaborated on a number of investment opportunities. Our relationship expanded further in 2002 when we co-founded the Mid America Healthcare Investor Network (MHIN), an organization of more than 50 venture capital funds that focus on life science opportunities." MHIN is now recognized as one of the most active and productive venture capital associations in the country.

It was through MHIN that Broderick developed a close rapport with Prolog's other partners -- Ilya Nykin and Brian Clevinger. After Broderick's fund invested in ZyStor Therapeutics, one of the most promising ventures in Prolog's portfolio, he joined Clevinger on the company's board of directors. The two also have served together at several industry organizations including BioGenerator, InvestMidwest, and BIO Mid-America Venture Forum.

"I was attracted to Prolog because it has one of the most innovative and effective investment teams in the venture capital business," said Broderick. "I especially admire this firm for being committed since inception to balancing traditional healthcare investing with focused and resourceful pursuit of opportunities in emerging areas of life science. I am convinced this investment approach is the wave of the future and am excited to help the firm build on its early leadership position."

Prolog is a venture capital firm specializing in life science investing. Since its launch in 2001, Prolog has financed more than 20 early-stage companies. The firm is managed by a team of professionals with extensive experience as both investors and entrepreneurs. Prolog focuses on traditional healthcare opportunities as well as emerging areas - such as nutrition, wellness, plant science, and enabling platforms - in which it has built one of the largest portfolios in the country. For more information, visit http://www.prologventures.com.


'/>"/>
SOURCE Prolog Ventures
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Visions: Broderick says Wisconsin should be in top third in venture capital
2. Chemical-petroleum executive joins Virent Energy board
3. Schneider National exec joins TrafficCast board
4. Doyle joins governors in support of stem cell bill
5. Genomics researcher Hood joins NimbleGen board
6. Fergus joins Baird Venture Partners, Caden Bio
7. Meier joins Broadlook Technologies as COO
8. Prodesse joins forces with Invitrogen
9. Wisconsin joins price-fixing suit vs. D-RAM makers
10. Napier joins board of Third Wave Technologies
11. Schmidt rejoins Renaissance Learning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 Non-profit Consortium Aims to ... to Support Research and Discovery --> ... an ambitious plan to sequence 100,000 individuals. It is intended ... at least 7 of North and East Asian countries. ... phase, the project will focus on creating phased reference genomes ...
(Date:2/11/2016)... Feb. 11, 2016  Spectra BioPharma Selling Solutions (Spectra) ... provides biopharma companies the experience, expertise, operational delivery ... outsourced sales teams. Created in concert with industry ... the strategic and tactical needs of its clients ... through both personal and non-personal promotion. ...
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant ... report, "Stem Cell Research Products, Opportunities, Tools, and Technologies ... ... in the stem cell industry, BioInformant has more than ... the stem cell market, by stem cell type. This ...
(Date:2/10/2016)... Early-career researchers from ... , Uganda and Yemen ... nutrition   Indonesia , Nepal ... Yemen are being honored for their accomplishments in ... celebrated for mentoring young women scientists who are pursuing careers in agriculture, ...
Breaking Biology Technology:
(Date:2/3/2016)... PUNE, India , February 3, 2016 ... to the new market research report "Automated Fingerprint Identification ... (Tenprint Search, Latent Search), Application (Banking & Finance, Government, ... 2020", published by MarketsandMarkets, the market is expected to ... estimated CAGR of 21.0% between 2015 and 2020. The ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
Breaking Biology News(10 mins):